
Jose A Villadangos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/847906/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunological Reviews, 2004, 199, 9-26.	6.0	641
2	Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming. Immunity, 2006, 25, 153-162.	14.3	637
3	Cathepsin L: Critical Role in Ii Degradation and CD4 T Cell Selection in the Thymus. Science, 1998, 280, 450-453.	12.6	624
4	Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nature Reviews Immunology, 2007, 7, 543-555.	22.7	573
5	Essential Role for Cathepsin S in MHC Class Il–Associated Invariant Chain Processing and Peptide Loading. Immunity, 1996, 4, 357-366.	14.3	502
6	Cutting Edge: Generation of Splenic CD8+ and CD8â^ Dendritic Cell Equivalents in Fms-Like Tyrosine Kinase 3 Ligand Bone Marrow Cultures. Journal of Immunology, 2005, 174, 6592-6597.	0.8	491
7	Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development. Immunity, 1999, 10, 197-206.	14.3	486
8	Antigen-Presentation Properties of Plasmacytoid Dendritic Cells. Immunity, 2008, 29, 352-361.	14.3	449
9	Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nature Immunology, 2004, 5, 1143-1148.	14.5	387
10	The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10729-10734.	7.1	357
11	Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood, 2003, 102, 2187-2194.	1.4	319
12	The Molecular Signature of Tissue Resident Memory CD8 T Cells Isolated from the Brain. Journal of Immunology, 2012, 189, 3462-3471.	0.8	310
13	Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nature Immunology, 2006, 7, 165-172.	14.5	308
14	Butyrophilin 2A1 is essential for phosphoantigen reactivity by $\hat{I}^3\hat{I}^{\prime}$ T cells. Science, 2020, 367, .	12.6	275
15	Cathepsin S activity regulates antigen presentation and immunity Journal of Clinical Investigation, 1998, 101, 2351-2363.	8.2	273
16	Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4516-4521.	7.1	248
17	A molecular basis underpinning the T cell receptor heterogeneity of mucosal-associated invariant T cells. Journal of Experimental Medicine, 2014, 211, 1585-1600.	8.5	245
18	Proteases involved in MHC dass II antigen presentation. Immunological Reviews, 1999, 172, 109-120.	6.0	223

#	Article	IF	CITATIONS
19	Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic Cells. Journal of Cell Biology, 1999, 147, 775-790.	5.2	210
20	Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nature Immunology, 2008, 9, 1244-1252.	14.5	202
21	Enhanced survival of lung tissue-resident memory CD8+ T cells during infection with influenza virus due to selective expression of IFITM3. Nature Immunology, 2013, 14, 238-245.	14.5	186
22	Degradation of Mouse Invariant Chain: Roles of Cathepsins S and D and the Influence of Major Histocompatibility Complex Polymorphism. Journal of Experimental Medicine, 1997, 186, 549-560.	8.5	185
23	Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis. Blood, 2004, 103, 2187-2195.	1.4	182
24	Blood-stage <i>Plasmodium</i> infection induces CD8 ⁺ T lymphocytes to parasite-expressed antigens, largely regulated by CD8î± ⁺ dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14509-14514.	7.1	179
25	Proteolysis in MHC Class II Antigen Presentation. Immunity, 2000, 12, 233-239.	14.3	177
26	Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood, 2005, 105, 2465-2472.	1.4	175
27	Cutting Edge: Conventional CD8α+ Dendritic Cells Are Preferentially Involved in CTL Priming After Footpad Infection with Herpes Simplex Virus-1. Journal of Immunology, 2003, 170, 4437-4440.	0.8	171
28	DEC-205 is a cell surface receptor for CpG oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16270-16275.	7.1	155
29	Selective suicide of cross-presenting CD8 ⁺ dendritic cells by cytochrome <i>c</i> injection shows functional heterogeneity within this subset. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3029-3034.	7.1	151
30	Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20377-20381.	7.1	150
31	MHC Class II Expression Is Regulated in Dendritic Cells Independently of Invariant Chain Degradation. Immunity, 2001, 14, 739-749.	14.3	141
32	Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunological Reviews, 2005, 207, 191-205.	6.0	139
33	Regulation of Antigen Presentation and Cross-Presentation in the Dendritic Cell Network: Facts, Hypothesis, and Immunological Implications. Advances in Immunology, 2005, 86, 241-305.	2.2	138
34	Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: Limitations of the Langerhans cells paradigm. Seminars in Immunology, 2005, 17, 262-272.	5.6	138
35	The cell biology of crossâ€presentation and the role of dendritic cell subsets. Immunology and Cell Biology, 2008, 86, 353-362.	2.3	136
36	Antigen presentation by dendritic cells in vivo. Current Opinion in Immunology, 2009, 21, 105-110.	5.5	136

#	Article	IF	CITATIONS
37	Local Modulation of Antigen-Presenting Cell Development after Resolution of Pneumonia Induces Long-Term Susceptibility to Secondary Infections. Immunity, 2017, 47, 135-147.e5.	14.3	133
38	Alveolar macrophages are epigenetically altered after inflammation, leading to long-term lung immunoparalysis. Nature Immunology, 2020, 21, 636-648.	14.5	128
39	The intracellular pathway for the presentation of vitamin B–related antigens by the antigen-presenting molecule MR1. Nature Immunology, 2016, 17, 531-537.	14.5	127
40	Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. Mucosal Immunology, 2015, 8, 1060-1071.	6.0	124
41	Endolysosomal proteases and their inhibitors in immunity. Nature Reviews Immunology, 2009, 9, 871-882.	22.7	114
42	Found in translation: the human equivalent of mouse CD8+ dendritic cells. Journal of Experimental Medicine, 2010, 207, 1131-1134.	8.5	111
43	Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. Journal of Experimental Medicine, 2007, 204, 2579-2590.	8.5	108
44	The Acquisition of Antigen Cross-Presentation Function by Newly Formed Dendritic Cells. Journal of Immunology, 2011, 186, 5184-5192.	0.8	101
45	Presentation of antigens by MHC class II molecules: getting the most out of them. Molecular Immunology, 2001, 38, 329-346.	2.2	93
46	Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Tollâ€like receptor signaling. Immunology and Cell Biology, 2008, 86, 200-205.	2.3	90
47	Characterization of an Immediate Splenic Precursor of CD8+ Dendritic Cells Capable of Inducing Antiviral T Cell Responses. Journal of Immunology, 2009, 182, 4200-4207.	0.8	86
48	GMâ€CSF increases crossâ€presentation and CD103 expression by mouse CD8 ⁺ spleen dendritic cells. European Journal of Immunology, 2011, 41, 2585-2595.	2.9	86
49	Organ-specific isoform selection of fatty acid–binding proteins in tissue-resident lymphocytes. Science Immunology, 2020, 5, .	11.9	85
50	Invariant Chain Controls the Activity of Extracellular Cathepsin L. Journal of Experimental Medicine, 2002, 196, 1263-1270.	8.5	81
51	Lymphoid organ dendritic cells: beyond the Langerhans cells paradigm. Immunology and Cell Biology, 2004, 82, 91-98.	2.3	81
52	Regulation of CD1 Function and NK1.1+ T Cell Selection and Maturation by Cathepsin S. Immunity, 2001, 15, 909-919.	14.3	75
53	The Protease Inhibitor Cystatin C Is Differentially Expressed among Dendritic Cell Populations, but Does Not Control Antigen Presentation. Journal of Immunology, 2003, 171, 5003-5011.	0.8	74
54	Differential use of autophagy by primary dendritic cells specialized in cross-presentation. Autophagy, 2015, 11, 906-917.	9.1	74

#	Article	IF	CITATIONS
55	Differentiation of Inflammatory Dendritic Cells Is Mediated by NF-κB1–Dependent GM-CSF Production in CD4 T Cells. Journal of Immunology, 2011, 186, 5468-5477.	0.8	72
56	Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia. Lancet Respiratory Medicine,the, 2019, 7, 710-720.	10.7	66
57	Downregulation of MHC Class I Expression by Influenza A and B Viruses. Frontiers in Immunology, 2019, 10, 1158.	4.8	65
58	Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17753-17758.	7.1	64
59	Criteria for Dendritic Cell Receptor Selection for Efficient Antibody-Targeted Vaccination. Journal of Immunology, 2015, 194, 2696-2705.	0.8	63
60	Destructive potential of the aspartyl protease cathepsin D in MHC class Ilâ€restricted antigen processing. European Journal of Immunology, 2005, 35, 3442-3451.	2.9	60
61	A Modular and Combinatorial View of the Antigen Crossâ€Presentation Pathway in Dendritic Cells. Traffic, 2011, 12, 1677-1685.	2.7	60
62	The inflammatory cytokine, <scp>GM</scp> â€ <scp>CSF</scp> , alters the developmental outcome of murine dendritic cells. European Journal of Immunology, 2012, 42, 2889-2900.	2.9	55
63	Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. Journal of Experimental Medicine, 2016, 213, 1695-1703.	8.5	55
64	Absence of mucosal-associated invariant T cells in a person with a homozygous point mutation in <i>MR1</i> . Science Immunology, 2020, 5, .	11.9	50
65	MR1 presentation of vitamin B-based metabolite ligands. Current Opinion in Immunology, 2015, 34, 28-34.	5.5	46
66	Cytotoxic T Lymphocytes from Cathepsin B-deficient Mice Survive Normally in Vitro and in Vivo after Encountering and Killing Target Cells. Journal of Biological Chemistry, 2006, 281, 30485-30491.	3.4	45
67	A Natural Peptide Antigen within the Plasmodium Ribosomal Protein RPL6 Confers Liver TRM Cell-Mediated Immunity against Malaria in Mice. Cell Host and Microbe, 2020, 27, 950-962.e7.	11.0	45
68	Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. Molecular Immunology, 2010, 47, 1765-1773.	2.2	44
69	IL-10 Controls Cystatin C Synthesis and Blood Concentration in Response to Inflammation through Regulation of IFN Regulatory Factor 8 Expression. Journal of Immunology, 2011, 186, 3666-3673.	0.8	43
70	Dendritic Cell Migration and Antigen Presentation Are Coordinated by the Opposing Functions of the Tetraspanins CD82 and CD37. Journal of Immunology, 2016, 196, 978-987.	0.8	43
71	Factors determining the spontaneous activation of splenic dendritic cells in culture. Innate Immunity, 2011, 17, 338-352.	2.4	42
72	Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. EMBO Journal, 2000, 19, 882-891.	7.8	41

#	Article	IF	CITATIONS
73	Changes in the repertoire of peptides bound to HLA-B27 subtypes and to site-specific mutants inside and outside pocket B Journal of Experimental Medicine, 1993, 177, 613-620.	8.5	40
74	Outside looking in: the inner workings of the crosspresentation pathway within dendritic cells. Trends in Immunology, 2007, 28, 45-47.	6.8	40
75	Bloodâ€stage <i>Plasmodium berghei</i> infection leads to shortâ€lived parasiteâ€associated antigen presentation by dendritic cells. European Journal of Immunology, 2010, 40, 1674-1681.	2.9	40
76	Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3â^'/â^' mice. Molecular Immunology, 2012, 50, 9-17.	2.2	39
77	Binding of peptides naturally presented by HLA–B27 to the differentially disease–associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens, 1996, 48, 509-518.	1.0	38
78	Cognate CD4+ Help Elicited by Resting Dendritic Cells Does Not Impair the Induction of Peripheral Tolerance in CD8+ T Cells. Journal of Immunology, 2007, 178, 2094-2103.	0.8	38
79	Cutting Edge: B220+CCR9â~' Dendritic Cells Are Not Plasmacytoid Dendritic Cells but Are Precursors of Conventional Dendritic Cells. Journal of Immunology, 2009, 183, 1514-1517.	0.8	37
80	Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. Journal of Immunology, 1994, 152, 2317-23.	0.8	37
81	Resident and Monocyte-Derived Dendritic Cells Become Dominant IL-12 Producers under Different Conditions and Signaling Pathways. Journal of Immunology, 2010, 185, 2125-2133.	0.8	36
82	Hydrocortisone Prevents Immunosuppression by Interleukin-10+ Natural Killer Cells After Trauma-Hemorrhage. Critical Care Medicine, 2014, 42, e752-e761.	0.9	36
83	Endoplasmic reticulum chaperones stabilize ligand-receptive MR1 molecules for efficient presentation of metabolite antigens. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24974-24985.	7.1	36
84	Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science, 2022, 375, eabf7470.	12.6	36
85	Virus-Mediated Suppression of the Antigen Presentation Molecule MR1. Cell Reports, 2020, 30, 2948-2962.e4.	6.4	35
86	Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. European Journal of Immunology, 1995, 25, 2370-2377.	2.9	34
87	HLAâ€B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. Tissue Antigens, 1997, 49, 580-587.	1.0	34
88	Modulation of antigen presentation by intracellular trafficking. Current Opinion in Immunology, 2015, 34, 16-21.	5.5	34
89	Respiratory DC Use IFITM3 to Avoid Direct Viral Infection and Safeguard Virus-Specific CD8+ T Cell Priming. PLoS ONE, 2015, 10, e0143539.	2.5	34
90	MARCH ligases in immunity. Current Opinion in Immunology, 2019, 58, 38-43.	5.5	33

#	Article	IF	CITATIONS
91	Immune insufficiency during GVHD is due to defective antigen presentation within dendritic cell subsets. Blood, 2012, 119, 5918-5930.	1.4	32
92	Is it a DC, is it an NK? No, it's an IKDC. Nature Medicine, 2006, 12, 167-168.	30.7	30
93	Targeting antigen to bone marrow stromal cellâ€2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. European Journal of Immunology, 2013, 43, 595-605.	2.9	29
94	How MR1 Presents a Pathogen Metabolic Signature to Mucosal-Associated Invariant T (MAIT) Cells. Trends in Immunology, 2017, 38, 679-689.	6.8	29
95	MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS ONE, 2018, 13, e0200540.	2.5	29
96	Inflammation Conditions Mature Dendritic Cells To Retain the Capacity To Present New Antigens but with Altered Cytokine Secretion Function. Journal of Immunology, 2014, 193, 3851-3859.	0.8	27
97	Spatiotemporal Adaptations of Macrophage and Dendritic Cell Development and Function. Annual Review of Immunology, 2022, 40, 525-557.	21.8	27
98	A Critical Role for Granzymes in Antigen Cross-Presentation through Regulating Phagocytosis of Killed Tumor Cells. Journal of Immunology, 2011, 187, 1166-1175.	0.8	24
99	Control of MHC II antigen presentation by ubiquitination. Current Opinion in Immunology, 2013, 25, 109-114.	5.5	24
100	Developmental Regulation of Synthesis and Dimerization of the Amyloidogenic Protease Inhibitor Cystatin C in the Hematopoietic System. Journal of Biological Chemistry, 2014, 289, 9730-9740.	3.4	24
101	No driving without a license. Nature Immunology, 2005, 6, 125-126.	14.5	23
102	Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals. Current Opinion in Pharmacology, 2014, 17, 64-70.	3.5	23
103	The role of dendritic cell alterations in susceptibility to hospital-acquired infections during critical-illness related immunosuppression. Molecular Immunology, 2015, 68, 120-123.	2.2	22
104	Dendritic cell Flt3 – regulation, roles and repercussions for immunotherapy. Immunology and Cell Biology, 2021, 99, 962-971.	2.3	22
105	Role of binding pockets for amino-terminal peptide residues in HLA-B27 allorecognition. Journal of Immunology, 1992, 149, 505-10.	0.8	22
106	Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine, 2013, 31, 2310-2316.	3.8	21
107	MR1 antigen presentation to MAIT cells: new ligands, diverse pathways?. Current Opinion in Immunology, 2018, 52, 108-113.	5.5	21
108	Autophagy and Mechanisms of Effective Immunity. Frontiers in Immunology, 2012, 3, 60.	4.8	20

#	Article	IF	CITATIONS
109	Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT. Science Immunology, 2021, 6, .	11.9	19
110	CD69 Does Not Affect the Extent of T Cell Priming. PLoS ONE, 2012, 7, e48593.	2.5	19
111	Hold On, the Monocytes Are Coming!. Immunity, 2007, 26, 390-392.	14.3	17
112	Differential effect of CD69 targeting on bystander and antigen-specific T cell proliferation. Journal of Leukocyte Biology, 2012, 92, 145-158.	3.3	17
113	Serpinb9 is a marker of antigen cross-presenting dendritic cells. Molecular Immunology, 2017, 82, 50-56.	2.2	17
114	RNF41 regulates the damage recognition receptor Clec9A and antigen cross-presentation in mouse dendritic cells. ELife, 2020, 9, .	6.0	16
115	Structure of HLA-B27-specific T cell epitopes. Antigen presentation in B2703 is limited mostly to a subset of the antigenic determinants on B2705. European Journal of Immunology, 1994, 24, 2548-2555.	2.9	15
116	Serpinb9 (Spi6)â€deficient mice are impaired in dendritic cellâ€mediated antigen crossâ€presentation. Immunology and Cell Biology, 2012, 90, 841-851.	2.3	15
117	Rapid Deletion and Inactivation of CTLs upon Recognition of a Number of Target Cells over a Critical Threshold. Journal of Immunology, 2013, 191, 3534-3544.	0.8	15
118	Targeting the Gut Vascular Endothelium Induces Gut Effector CD8 T Cell Responses Via Cross-Presentation by Dendritic Cells. Journal of Immunology, 2007, 179, 5678-5685.	0.8	14
119	Antibody-mediated targeting of antigen to C-type lectin-like receptors Clec9A and Clec12A elicits different vaccination outcomes. Molecular Immunology, 2017, 81, 143-150.	2.2	14
120	Induction of antigenâ€specific effectorâ€phase tolerance following vaccination against a previously ignored Bâ€cell lymphoma. Immunology and Cell Biology, 2011, 89, 595-603.	2.3	13
121	Consequences of direct and indirect activation of dendritic cells on antigen presentation: Functional implications and clinical considerations. Molecular Immunology, 2013, 55, 175-178.	2.2	13
122	Cross-reactive T cell clones from unrelated individuals reveal similarities in peptide presentation between HLA-B27 and HLA-DR2. Journal of Immunology, 1993, 150, 2675-86.	0.8	13
123	Unlocking autofluorescence in the era of full spectrum analysis: Implications for immunophenotype discovery projects. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 922-941.	1.5	13
124	Ubiquitin-like protein 3 (UBL3) is required for MARCH ubiquitination of major histocompatibility complex class II and CD86. Nature Communications, 2022, 13, 1934.	12.8	13
125	Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model. Journal of Immunology, 2016, 196, 3935-3942.	0.8	12
126	Understanding host–pathogen interaction. Intensive Care Medicine, 2016, 42, 2084-2086.	8.2	12

#	Article	IF	CITATIONS
127	Endogenous Murine BST-2/Tetherin Is Not a Major Restriction Factor of Influenza A Virus Infection. PLoS ONE, 2015, 10, e0142925.	2.5	12
128	Antigenâ€specific impairment of adoptive Tâ€cell therapy against cancer: players, mechanisms, solutions and a hypothesis. Immunological Reviews, 2016, 272, 169-182.	6.0	11
129	DNAâ€based probes for flow cytometry analysis of endocytosis and recycling. Traffic, 2017, 18, 242-249.	2.7	11
130	MR1: a multi-faceted metabolite sensor for T cell activation. Current Opinion in Immunology, 2020, 64, 124-129.	5.5	11
131	Varicella Zoster Virus Impairs Expression of the Nonclassical Major Histocompatibility Complex Class I–Related Gene Protein (MR1). Journal of Infectious Diseases, 2023, 227, 391-401.	4.0	11
132	Ubiquitination of MHC Class II Is Required for Development of Regulatory but Not Conventional CD4+ T Cells. Journal of Immunology, 2020, 205, 1207-1216.	0.8	10
133	MHC Class II Ubiquitination Regulates Dendritic Cell Function and Immunity. Journal of Immunology, 2021, 207, 2255-2264.	0.8	10
134	Regulation of dendritic cell function by Fc-Î ³ -receptors and the neonatal Fc receptor. Molecular Immunology, 2021, 139, 193-201.	2.2	10
135	Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor 9 ligand. European Journal of Immunology, 2005, 35, 3209-3220.	2.9	9
136	CD36 family members are TCR-independent ligands for CD1 antigen–presenting molecules. Science Immunology, 2021, 6, .	11.9	7
137	Membrane-associated RING-CH (MARCH) proteins down-regulate cell surface expression of the interleukin-6 receptor alpha chain (IL6Rα). Biochemical Journal, 2019, 476, 2869-2882.	3.7	7
138	Tâ€cell receptor usage in alloreactivity against HLAâ€B <i>*</i> 2703 reveals significant conservation of the antigenic structure of B <i>*</i> 2705. Tissue Antigens, 1996, 47, 478-484.	1.0	6
139	Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect of presenilin exon 9 deletion on gamma- and epsilon-cleavage. FEBS Journal, 2003, 270, 495-506.	0.2	6
140	Antigen processing and recognition. Current Opinion in Immunology, 2007, 19, 63-65.	5.5	5
141	Shutdown of immunological priming and presentation after in vivo administration of adenovirus. Gene Therapy, 2012, 19, 1095-1100.	4.5	5
142	Physiological substrates and ontogeny-specific expression of the ubiquitin ligases MARCH1 and MARCH8. Current Research in Immunology, 2021, 2, 218-228.	2.8	5
143	MAIT cells accumulate in ovarian cancer-elicited ascites where they retain their capacity to respond to MR1 ligands and cytokine cues. Cancer Immunology, Immunotherapy, 2022, 71, 1259-1273.	4.2	5
144	Reply to Burgdorf et al.: The mannose receptor is not involved in antigen cross-presentation by steady-state dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, .	7.1	4

#	Article	IF	CITATIONS
145	Antigen-presenting cells look within during influenza infection. Nature Medicine, 2015, 21, 1123-1125.	30.7	4
146	Differential antigenic requirements by diverse MR1â€restricted T cells. Immunology and Cell Biology, 2022, 100, 112-126.	2.3	3
147	Antigen processing. Current Opinion in Immunology, 2013, 25, 71-73.	5.5	2
148	Editorial overview: New proteins, cellular processes and intercellular interactions involved in antigen presentation. Current Opinion in Immunology, 2019, 58, iii-iv.	5.5	2
149	Ubiquitin Ligase MARCH8 attenuates Graft versus Host Disease via Regulation of Gut Epithelial Cell Surface MHC II Expression Transplantation, 2018, 102, S300.	1.0	1
150	Peptide binding to the differentially disease-associated HLA-B*2704 and B*2706 and to mutants mimicking their polimorphism. Human Immunology, 1996, 47, 18.	2.4	0
151	T-cell receptor usage in alloreactivity against HLA-B*2703 reveals much conservation of the antigenic structure of B*2705. Human Immunology, 1996, 47, 108.	2.4	0
152	Antigen-presenting cells and antigen presentation. , 2008, , 103-111.		0
153	Immune Insufficiency After Experimental Transplantation Is Due to Defective Antigen Presentation Within Dendritic Cell Subsets. Biology of Blood and Marrow Transplantation, 2012, 18, S225.	2.0	0
154	Role of UNC93B1 in the MHC class I cross presentation pathway. Molecular Immunology, 2012, 51, 24-25.	2.2	0
155	Indirectly activated dendritic cells are able to present antigens after maturation through sustained MHCII sysnthesis. Molecular Immunology, 2012, 51, 35.	2.2	0
156	Reply to: "Differential expression of serpins may selectively license distinct granzyme B functions including antigen cross-presentation― Molecular Immunology, 2017, 87, 327-328.	2.2	0
157	The MARCH family joins the antigen crossâ€presentation party. Immunology and Cell Biology, 2017, 95, 737-738.	2.3	0